Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | KDM4B | O94953 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17559145 | 0.93 | KDM4E (0.59) | KDM4ETP53PARP1ALOX5ADORA3 | |
| SCHEMBL21676727 | 0.80 | ALOX5 (0.56) | KDM4ETP53PARP1ALOX5ADORA3 | |
| SCHEMBL21676751 | 0.80 | ALOX5 (0.56) | KDM4ETP53PARP1ALOX5ADORA3 | |
| SCHEMBL18256632 | 0.80 | KDM4E (0.43) | KDM4ETP53PARP1ADORA3ADORA2A | |
| SCHEMBL1101962 | 0.75 | KDM4E (1.00) | KDM4ETP53ALOX5ADORA3ADORA2A | |
| SCHEMBL31091767 | 0.75 | KDM4E (1.00) | KDM4ETP53ALOX5ADORA3ADORA2A | |
| SCHEMBL22721914 | 0.72 | HPGD (0.54) | PARP1GAAMAPK1 | |
| SCHEMBL30976429 | 0.71 | ALDH1A1 (0.42) | KDM4EPARP1ALOX5ADORA3ADORA2A | |
| SCHEMBL30349694 | 0.70 | PARP1 (0.53) | KDM4EPARP1ALOX5FEN1KDM4C | |
| SCHEMBL18895771 | 0.70 | PARP1 (0.53) | KDM4EPARP1ALOX5FEN1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619387-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024108131-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3189049-B1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-107074824-B | Phthalazine derivatives of formula (I) as PCAF and GCN5 inhibitors for the treatment of cancer | 基因泰克公司 | 2021-01-08 | — | — | CN | disclosed |
| US-10155764-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC (US) | 2018-12-18 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3189049-A1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016036954-A1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016036954-A1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC1 | KDM4E 1061/4885TP53 4185/4885PARP1 1541/4885 |
| US-10155764-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC1 | KDM4E 1061/4885TP53 4185/4885PARP1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.